Literature DB >> 17221343

How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate.

J Pascual1, Y El Berdei, J C Gómez-Sánchez.   

Abstract

The usual recommended duration of preventive treatment for migraine is 3-6 months. Our aim was to explore how many patients attending a specialised clinic need prolonged preventive treatment for longer than one year. Eighty consecutive migraine patients who received preventive treatment with topiramate for 3 months with good response and tolerability were included in this observational study. All patients continued on topiramate until they had completed 6 months, when this drug was stopped. Topiramate was reintroduced if there was a worsening. Topiramate was kept for 6 more months and then discontinued again. Those patients whose headaches became worse after this second withdrawal received topiramate again and were followed-up for at least half a year. Headaches did not worsen after the first withdrawal at 6 months in 40 patients (50%), while they clearly worsened in the remaining 40 patients. At the end of the first year only two patients out of these 40 (5%) discontinued topiramate and did not notice an increase in headache frequency after two months. In conclusion, around half of the patients attending a specialised clinic due to frequent headache need preventive treatment for more than one year. Our data suggest that the current practice recommending periods of preventive treatment of 3-6 months should be reconsidered for many patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17221343      PMCID: PMC3476126          DOI: 10.1007/s10194-007-0351-x

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   7.277


  4 in total

1.  Recent advances in the pharmacological management of migraine.

Authors:  Julio Pascual
Journal:  F1000 Med Rep       Date:  2009-05-08

2.  Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting.

Authors:  Gereon Nelles; Lukas Schmitt; Thomas Humbert; Veit Becker; Petra Sandow; Karin Bornhoevd; Dirk Fritzsche; Barbara Schäuble
Journal:  J Headache Pain       Date:  2009-11-06       Impact factor: 7.277

3.  Field testing of the ICHD-3β and expert opinion criteria for chronic migraine.

Authors:  Huahua Jiang; Yong Deng; Yixin Zhang; Jieli Jin; Xueying Kong; Qiuwen Zhu; Kuiyun Wang; Jiying Zhou
Journal:  J Headache Pain       Date:  2016-09-19       Impact factor: 7.277

4.  Outcomes of topiramate for prophylaxis of chronic migraine headache.

Authors:  Khawar Ahmed; Hussain Rafiq; Shalmeen Tariq
Journal:  Pak J Med Sci       Date:  2022 Jul-Aug       Impact factor: 2.340

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.